FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204308029> ?p ?o ?g. }

• W3204308029 endingPage "3781" @default.
• W3204308029 startingPage "3771" @default.
• W3204308029 abstract "The use of tyrosine kinase inhibitors (TKIs) is associated with incident creatine kinase (CK) elevation in the treatment of advanced non-small cell lung cancer (NSCLC) patients. However, whether higher CK levels are associated with better antitumor responses or survival remains to be explored. We intend to investigate the clinical correlation between CK levels and TKI efficacy in advanced NSCLC.In this retrospective study, we enrolled 135 patients with stage IV NSCLC receiving TKI-based therapy in our center between June 2012 to July 2020. CK levels were monitored from the initiation of TKI medication and during the administration period. An X-tile analysis provided the optimal cutoff point for higher baseline CK. Patients were identified and grouped according to their baseline CK level and fold changes during TKI therapy. The primary endpoints included progression-free survival (PFS) and overall survival (OS), and the objective response rate (ORR) was calculated as the secondary endpoint.Among the 135 patients included in our study, those with higher baseline CK levels (≥70 U/L) had favorable PFS (15.2 vs. 8.8 months; P=0.028), while patients with significantly elevated CK (the highest CK value/baseline CK value ≥2 times) appeared to gain better PFS (14.6 vs. 10.0 months; P=0.139). The overall ORR was 67.4%. Patients with higher baseline CK levels had numerically higher ORR (74.6% vs. 60.3%; P=0.076). Similarly, patients with significant CK elevation had a superior 4-month PFS rate (77.6% vs. 59.7%; P=0.029). Results from the subgroup analyses were identical to the overall ones. For patients with higher baseline CK levels, those experiencing significant CK elevation had prolonged PFS (17.2 vs. 14.2 months; P=0.038); a same trend was obtained from the lower baseline CK group (<70 U/L) (9.4 vs. 7.9 months; P=0.038). In multivariable analysis, higher baseline CK level and significant CK elevation remained statistically associated with PFS, with hazard ratios of 0.48 and 0.59, respectively.Both higher baseline CK levels and significant CK elevation after treatment were correlated with prolonged PFS in NSCLC treated with TKIs, suggesting the potential prognostic and predictive impact of CK level on these patients." @default.
• W3204308029 created "2021-10-11" @default.
• W3204308029 creator A5004809139 @default.
• W3204308029 creator A5014237587 @default.
• W3204308029 creator A5021534329 @default.
• W3204308029 creator A5023871304 @default.
• W3204308029 creator A5031255136 @default.
• W3204308029 creator A5033215610 @default.
• W3204308029 creator A5047191354 @default.
• W3204308029 creator A5058569122 @default.
• W3204308029 creator A5065394940 @default.
• W3204308029 creator A5071806695 @default.
• W3204308029 creator A5074447759 @default.
• W3204308029 creator A5077911190 @default.
• W3204308029 date "2021-09-01" @default.
• W3204308029 modified "2023-10-06" @default.
• W3204308029 title "Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors" @default.
• W3204308029 cites W1511593813 @default.
• W3204308029 cites W1533005819 @default.
• W3204308029 cites W1585093095 @default.
• W3204308029 cites W1849159432 @default.
• W3204308029 cites W1990626198 @default.
• W3204308029 cites W1993917607 @default.
• W3204308029 cites W1998990808 @default.
• W3204308029 cites W1999966467 @default.
• W3204308029 cites W2013030792 @default.
• W3204308029 cites W2031149260 @default.
• W3204308029 cites W2041686985 @default.
• W3204308029 cites W2047382816 @default.
• W3204308029 cites W2066906261 @default.
• W3204308029 cites W2104830962 @default.
• W3204308029 cites W2125082756 @default.
• W3204308029 cites W2133650808 @default.
• W3204308029 cites W2149456801 @default.
• W3204308029 cites W2153942285 @default.
• W3204308029 cites W2157174922 @default.
• W3204308029 cites W2159594706 @default.
• W3204308029 cites W2161821474 @default.
• W3204308029 cites W2164452916 @default.
• W3204308029 cites W2791927015 @default.
• W3204308029 cites W2797760005 @default.
• W3204308029 cites W2917837889 @default.
• W3204308029 cites W3085485176 @default.
• W3204308029 cites W3128646645 @default.
• W3204308029 cites W3135105663 @default.
• W3204308029 doi "https://doi.org/10.21037/tlcr-21-600" @default.
• W3204308029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8512461" @default.
• W3204308029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34733627" @default.
• W3204308029 hasPublicationYear "2021" @default.
• W3204308029 type Work @default.
• W3204308029 sameAs 3204308029 @default.
• W3204308029 citedByCount "2" @default.
• W3204308029 countsByYear W32043080292022 @default.
• W3204308029 countsByYear W32043080292023 @default.
• W3204308029 crossrefType "journal-article" @default.
• W3204308029 hasAuthorship W3204308029A5004809139 @default.
• W3204308029 hasAuthorship W3204308029A5014237587 @default.
• W3204308029 hasAuthorship W3204308029A5021534329 @default.
• W3204308029 hasAuthorship W3204308029A5023871304 @default.
• W3204308029 hasAuthorship W3204308029A5031255136 @default.
• W3204308029 hasAuthorship W3204308029A5033215610 @default.
• W3204308029 hasAuthorship W3204308029A5047191354 @default.
• W3204308029 hasAuthorship W3204308029A5058569122 @default.
• W3204308029 hasAuthorship W3204308029A5065394940 @default.
• W3204308029 hasAuthorship W3204308029A5071806695 @default.
• W3204308029 hasAuthorship W3204308029A5074447759 @default.
• W3204308029 hasAuthorship W3204308029A5077911190 @default.
• W3204308029 hasBestOaLocation W32043080291 @default.
• W3204308029 hasConcept C126322002 @default.
• W3204308029 hasConcept C143998085 @default.
• W3204308029 hasConcept C203092338 @default.
• W3204308029 hasConcept C2776256026 @default.
• W3204308029 hasConcept C2779177807 @default.
• W3204308029 hasConcept C2780739268 @default.
• W3204308029 hasConcept C3019894029 @default.
• W3204308029 hasConcept C36880943 @default.
• W3204308029 hasConcept C535046627 @default.
• W3204308029 hasConcept C71924100 @default.
• W3204308029 hasConcept C81729549 @default.
• W3204308029 hasConcept C90924648 @default.
• W3204308029 hasConceptScore W3204308029C126322002 @default.
• W3204308029 hasConceptScore W3204308029C143998085 @default.
• W3204308029 hasConceptScore W3204308029C203092338 @default.
• W3204308029 hasConceptScore W3204308029C2776256026 @default.
• W3204308029 hasConceptScore W3204308029C2779177807 @default.
• W3204308029 hasConceptScore W3204308029C2780739268 @default.
• W3204308029 hasConceptScore W3204308029C3019894029 @default.
• W3204308029 hasConceptScore W3204308029C36880943 @default.
• W3204308029 hasConceptScore W3204308029C535046627 @default.
• W3204308029 hasConceptScore W3204308029C71924100 @default.
• W3204308029 hasConceptScore W3204308029C81729549 @default.
• W3204308029 hasConceptScore W3204308029C90924648 @default.
• W3204308029 hasIssue "9" @default.
• W3204308029 hasLocation W32043080291 @default.
• W3204308029 hasLocation W32043080292 @default.
• W3204308029 hasLocation W32043080293 @default.
• W3204308029 hasLocation W32043080294 @default.
• W3204308029 hasOpenAccess W3204308029 @default.

• next